Varda Space Industries is a Space & ISR company founded in 2020 and based in El Segundo, United States. It has raised $391M in total funding, most recently a Series C in 2026.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Aug 21, 2026 | Series C | $250M | — | — |
| Apr 5, 2024 | Series B | $90M | — | Caffeinated Capital |
| Jul 29, 2021 |
| Series A |
| $42M |
| — |
| Khosla Ventures, Caffeinated Capital |
| Dec 8, 2020 | Seed | $9M | — | Founders Fund, Lux Capital |
No articles ingested yet for Varda Space Industries. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Autonomous orbital manufacturing and return vehicles that process pharmaceuticals and materials in microgravity then reenter Earth's atmosphere and land on demand. Four missions flown as of mid-2025: W-1 through W-3 completed with successful reentries in Utah and South Australia; W-4 launched June 2025 with in-house built satellite bus. Each capsule carries Air Force Research Laboratory payloads alongside commercial pharmaceutical experiments, making Varda a dual-use defense reentry testbed and commercial drug manufacturer simultaneously.
Integrated microgravity processing system that crystallizes small-molecule drugs and biologics—including monoclonal antibodies—in orbit, where the absence of gravity enables superior crystal uniformity and purity versus Earth-based production. Varda's first client, Improved Packing for Proteins (ritonavir experiments), demonstrated pharmaceutical-grade results. A $187M Series C in 2025 scaled operations toward 20 reentries contracted with Southern Launch through 2028, cementing Varda as the first commercial in-space factory.